Skip to the map

PDAC pipeline landscape

360 active PDAC programs, by approach (rows) and stage (columns).

Pipeline View

Small moleculeOligonucleotideGene therapy / editingAntibody / biologicUndisclosedRepurposingPossibly inactiveClick a chip for details
Setting:
Active PDAC programs by modality (rows) and stage (columns)
ModalityPreclinicalINDPhase 1Phase 2Phase 3+Approved
RAS and growth signalingKRAS allele-specific, pan-KRAS and pan-RAS inhibitors, KRAS degraders and RNAi, SOS1/SHP2, RAF/MEK/ERK, EGFR/HER2/NRG1, PI3K/AKT/mTOR, CDK
Synthetic lethality and DNA damage responsePARP, ATR, WEE1, POLQ, PRMT5/MAT2A in MTAP-deleted tumors, replication stress
Targeted payload deliveryAntibody-drug conjugates (e.g. Claudin 18.2, TROP2, mesothelin), radioconjugates, targeted nanoparticle cytotoxics
Checkpoint and T-cell activationPD-1/PD-L1, CTLA-4, LAG-3 and other checkpoints, bispecific T-cell engagers, cytokines acting on T cells
Cell therapies and vaccinesCAR-T, TCR-T, NK cells, mRNA and peptide neoantigen vaccines, KRAS vaccines, dendritic-cell vaccines
Innate immunity, myeloid cells and stromaCD40, CSF1R, CXCR2/CCR2, CD47, STING/TLR, oncolytic viruses, cancer-associated fibroblasts, hyaluronan, FAK, TGF-beta, CTGF
Metabolism, epigenetics and cell deathMitochondrial and glutamine metabolism, autophagy, iron and ferroptosis, epigenetic regulators (DNMT, HDAC, BET), apoptosis
UndisclosedMechanism not public
RepurposingAcademic trials of approved drugs, supplements, vitamins or herbal products